Commonly used diabetes drugs could lower the risk of cardiometabolic conditions but heighten the risk of gastrointestinal and ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

Furthermore, there is a growing trend towards the adoption of technologically advanced solutions, such as digital health platforms and telemedicine, for diabetes management. Leveraging these ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

The study in Nature Medicine explores the potential wider benefits and risks of diabetes drugs GLP-1 receptor agonists.

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...